Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands

Review
First Online:
Received:
Accepted:

Abstract

Many studies point toward the nociceptin/orphanin FQ (N/OFQ) and the N/OFQ peptide receptor (NOP) as targets for the development of innovative drugs for treating affective disorders. It has been reported that the activation of NOP receptors produces anxiolytic-like effects in rodents in a large series of behavioral assays, i.e., elevated plus maze, light-dark aversion, operant conflict, fear-potentiated startle, pup ultrasonic vocalizations, and hole board tests. In contrast, the blockade of N/OFQ signaling obtained with NOP-selective antagonists promotes antidepressant-like effects in the forced swimming and tail suspension tests. In these assays, N/OFQ is inactive per se, but reverses the antidepressant-like effects of NOP antagonists. NOP receptor knockout mice show an antidepressant-like phenotype, and NOP antagonists are inactive in these animals. Thus, the activation of the NOP receptor seems to evoke anxiolytic-like effects while its blockade antidepressant-like effects. This appears to be a rather unique behavioral profile since the activation or the blockade of a given neuropeptide receptor produces, in most of the cases, both antidepressant- and anxiolytic-like effects. This particular behavioral profile, the possible mechanisms of action, and the therapeutic potential of NOP receptor ligands for the treatment of depression and anxiety disorders are discussed in this review article.

Keywords

Nociceptin/orphanin FQ NOP receptor Anxiety Depression Stress Animal behavior 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

This work was financially supported by the University of Ferrara (60% grant to GC) and the European Community (Marie Curie Incoming International Fellowship, 509520 - MOODNOP, to ECG).

References

  1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington DCGoogle Scholar
  2. Arjomand J, Cole S, Evans CJ (2002) Novel orphanin FQ/nociceptin transcripts are expressed in human immune cells. J Neuroimmunol 130:100–108PubMedGoogle Scholar
  3. Arletti R, Vitale G, Ruggieri V (2005) Nociceptin/orphanin FQ and chronic mild stress: effects of acute and subchronic treatment in the rat. XXXII Meeting of the Italian Society of Pharmacology, Naples, Italy (1–4 June), p 134Google Scholar
  4. Berthele A, Platzer S, Dworzak D, Schadrack J, Mahal B, Buttner A, Assmus HP, Wurster K, Zieglgansberger W, Conrad B, Tolle TR (2003) [3H]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain. Neuroscience 121:629–640PubMedGoogle Scholar
  5. Bignan GC, Connolly PJ, Middleton SA (2005) Recent advances towards the discovery of ORL-1 receptor agonists and antagonists. Expert Opin Ther Patents 15:357–388Google Scholar
  6. Blakley GG, Pohorecky LA, Benjamin D (2004) Behavioral and endocrine changes following antisense oligonucleotide-induced reduction in the rat NOP receptor. Psychopharmacology (Berl) 171:421–428Google Scholar
  7. Boom A, Mollereau C, Meunier JC, Vassart G, Parmentier M, Vanderhaeghen JJ, Schiffmann SN (1999) Distribution of the nociceptin and nocistatin precursor transcript in the mouse central nervous system. Neuroscience 91:991–1007PubMedGoogle Scholar
  8. Bourin M, Fiocco AJ, Clenet F (2001) How valuable are animal models in defining antidepressant activity? Hum Psychopharmacol 16:9–21PubMedGoogle Scholar
  9. Bowery NG, Bettler B, Froestl W, Gallagher JP, Marshall F, Raiteri M, Bonner TI, Enna SJ (2002) International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function. Pharmacol Rev 54:247–264PubMedGoogle Scholar
  10. Calo’ G, Bigoni R, Rizzi A, Guerrini R, Salvadori S, Regoli D (2000a) Nociceptin/orphanin FQ receptor ligands. Peptides 21:935–947PubMedGoogle Scholar
  11. Calo’ G, Guerrini R, Bigoni R, Rizzi A, Marzola G, Okawa H, Bianchi C, Lambert DG, Salvadori S, Regoli D (2000b) Characterization of [Nphe(1)]nociceptin(1–13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol 129:1183–1193PubMedGoogle Scholar
  12. Calo’ G, Guerrini R, Rizzi A, Salvadori S, Regoli D (2000c) Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol 129:1261–1283PubMedGoogle Scholar
  13. Calo’ G, Rizzi A, Bigoni R, Guerrini R, Salvadori S, Regoli D (2002a) Pharmacological profile of nociceptin/orphanin FQ receptors. Clin Exp Pharmacol Physiol 29:223–228PubMedGoogle Scholar
  14. Calo’ G, Rizzi A, Rizzi D, Bigoni R, Guerrini R, Marzola G, Marti M, McDonald J, Morari M, Lambert DG, Salvadori S, Regoli D (2002b) [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol 136:303–311Google Scholar
  15. Calo’ G, Guerrini R, Rizzi A, Salvadori S, Burmeister M, Kapusta DR, Lambert DG, Regoli D (2005) UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. CNS Drug Rev 11:97–112Google Scholar
  16. Ciccocioppo R, Panocka I, Polidori C, Regoli D, Massi M (1999) Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacology (Berl) 141:220–224Google Scholar
  17. Ciccocioppo R, Martin-Fardon R, Weiss F, Massi M (2001) Nociceptin/orphanin FQ inhibits stress- and CRF-induced anorexia in rats. Neuroreport 12:1145–1149PubMedGoogle Scholar
  18. Ciccocioppo R, Biondini M, Antonelli L, Wichmann J, Jenck F, Massi M (2002) Reversal of stress- and CRF-induced anorexia in rats by the synthetic nociceptin/orphanin FQ receptor agonist, Ro 64-6198. Psychopharmacology (Berl) 161:113–119Google Scholar
  19. Ciccocioppo R, Fedeli A, Economidou D, Policani F, Weiss F, Massi M (2003) The bed nucleus is a neuroanatomical substrate for the anorectic effect of corticotropin-releasing factor and for its reversal by nociceptin/orphanin FQ. J Neurosci 23:9445–9451PubMedGoogle Scholar
  20. Ciccocioppo R, Cippitelli A, Economidou D, Fedeli A, Massi M (2004) Nociceptin/orphanin FQ acts as a functional antagonist of corticotropin-releasing factor to inhibit its anorectic effect. Physiol Behav 82:63–68PubMedGoogle Scholar
  21. Clark MS, Kaiyala KJ (2003) Role of corticotropin-releasing factor family peptides and receptors in stress-related psychiatric disorders. Semin Clin Neuropsychiatry 8:119–136PubMedGoogle Scholar
  22. Connor M, Vaughan CW, Chieng B, Christie MJ (1996) Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro. Br J Pharmacol 119:1614–1618PubMedGoogle Scholar
  23. Cox BM, Chavkin C, Christie MJ, Civelli O, Evans C, Hamon MD, Hoellt V, Kieffer B, Kitchen I, McKnight AT, Meunier JC, Portoghese PS (2000) Opioid receptors. In: Girdlestone D (ed) The IUPHAR compendium of receptor characterization and classification, 2nd edn. IUPHAR Media, London, pp 321–333Google Scholar
  24. Cryan JF, Kaupmann K (2005) Don’t worry ‘B’ happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci 26:36–43PubMedGoogle Scholar
  25. Cryan JF, Mombereau C (2004) In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 9:326–357PubMedGoogle Scholar
  26. Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23:238–245PubMedGoogle Scholar
  27. Cryan JF, Mombereau C, Vassout A (2005) The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29:571–625PubMedGoogle Scholar
  28. Dautzenberg FM, Wichmann J, Higelin J, Py-Lang G, Kratzeisen C, Malherbe P, Kilpatrick GJ, Jenck F (2001) Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo. J Pharmacol Exp Ther 298:812–819PubMedGoogle Scholar
  29. Devine DP, Taylor L, Reinscheid RK, Monsma FJ Jr, Civelli O, Akil H (1996) Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ. Neurochem Res 21:1387–1396PubMedGoogle Scholar
  30. Fernandez F, Misilmeri MA, Felger JC, Devine DP (2004) Nociceptin/orphanin FQ increases anxiety-related behavior and circulating levels of corticosterone during neophobic tests of anxiety. Neuropsychopharmacology 29:59–71PubMedGoogle Scholar
  31. Fischer A, Forssmann WG, Undem BJ (1998) Nociceptin-induced inhibition of tachykinergic neurotransmission in guinea pig bronchus. J Pharmacol Exp Ther 285:902–907PubMedGoogle Scholar
  32. Gard PR (2004) Angiotensin as a target for the treatment of Alzheimer’s disease, anxiety and depression. Expert Opin Ther Targets 8:7–14PubMedGoogle Scholar
  33. Gavioli EC, Rae GA, Calo’ G, Guerrini R, De Lima TC (2002) Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test. Br J Pharmacol 136:764–772PubMedGoogle Scholar
  34. Gavioli EC, Marzola G, Guerrini R, Bertorelli R, Zucchini S, De Lima TC, Rae GA, Salvadori S, Regoli D, Calo’ G (2003) Blockade of nociceptin/orphanin FQ-NOP receptor signaling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci 17:1987–1990PubMedGoogle Scholar
  35. Gavioli EC, Vaughan CW, Marzola G, Guerrini R, Mitchell VA, Zucchini S, De Lima TC, Rae GA, Salvadori S, Regoli D, Calo’ G (2004) Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice. Naunyn-Schmiedeberg’s Arch Pharmacol 369:547–553Google Scholar
  36. Gilligan PJ, Li YW (2004) Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases. Curr Opin Drug Discov Devel 7:487–497PubMedGoogle Scholar
  37. Giuliani S, Tramontana M, Lecci A, Maggi CA (1997) Effect of nociceptin on heart rate and blood pressure in anaesthetized rats. Eur J Pharmacol 333:177–179PubMedGoogle Scholar
  38. Giuliani S, Lecci A, Tramontana M, Maggi CA (1998) The inhibitory effect of nociceptin on the micturition reflex in anaesthetized rats. Br J Pharmacol 124:1566–1572PubMedGoogle Scholar
  39. Gordon JA, Hen R (2004) The serotonergic system and anxiety. Neuromolecular Med 5:27–40PubMedGoogle Scholar
  40. Griebel G, Perrault G, Sanger DJ (1999) Orphanin FQ, a novel neuropeptide with anti-stress-like activity. Brain Res 836:221–224PubMedGoogle Scholar
  41. Griebel G, Stemmelin J, Gal CS, Soubrie P (2005) Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharm Des 11:1549–1559PubMedGoogle Scholar
  42. Gu H, Hu D, Hong XR, Mao J, Cui Y, Hui N, Sha JY (2003) Changes and significance of orphanin and serotonin in patients with postpartum depression. Zhonghua Fu Chan Ke Za Zhi 38:727–728PubMedGoogle Scholar
  43. Hawes BE, Graziano MP, Lambert DG (2000) Cellular actions of nociceptin: transduction mechanisms. Peptides 21:961–967PubMedGoogle Scholar
  44. Heilig M (2004) The NPY system in stress, anxiety and depression. Neuropeptides 38:213–224PubMedGoogle Scholar
  45. Heinricher MM (2003) Orphanin FQ/nociceptin: from neural circuitry to behavior. Life Sci 73:813–822PubMedGoogle Scholar
  46. Herpfer I, Lieb K (2005) Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 19:275–293PubMedGoogle Scholar
  47. Herranz R (2003) Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 23:559–605PubMedGoogle Scholar
  48. Holmes A, Yang RJ, Murphy DL, Crawley JN (2002) Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology 27:914–923PubMedGoogle Scholar
  49. Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G (2003) Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24:580–588PubMedGoogle Scholar
  50. Jenck F, Moreau JL, Martin JR, Kilpatrick GJ, Reinscheid RK, Monsma FJ Jr, Nothacker HP, Civelli O (1997) Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc Natl Acad Sci USA 94:14854–14858PubMedGoogle Scholar
  51. Jenck F, Wichmann J, Dautzenberg FM, Moreau JL, Ouagazzal AM, Martin JR, Lundstrom K, Cesura AM, Poli SM, Roever S, Kolczewski S, Adam G, Kilpatrick G (2000) A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc Natl Acad Sci USA 97:4938–4943PubMedGoogle Scholar
  52. Jones KA, Borowsky B, Tamm JA, Craig DA, Durkin MM, Dai M, Yao WJ, Johnson M, Gunwaldsen C, Huang LY, Tang C, Shen Q, Salon JA, Morse K, Laz T, Smith KE, Nagarathnam D, Noble SA, Branchek TA, Gerald C (1998) GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 396:674–679PubMedGoogle Scholar
  53. Kamei J, Matsunawa Y, Miyata S, Tanaka S, Saitoh A (2004) Effects of nociceptin on the exploratory behavior of mice in the hole-board test. Eur J Pharmacol 489:77–87PubMedGoogle Scholar
  54. Kapusta DR, Sezen SF, Chang JK, Lippton H, Kenigs VA (1997) Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphanin FQ). Life Sci 60:PL15–PL21PubMedGoogle Scholar
  55. Kapusta DR, Dayan LA, Kenigs VA (2002) Nociceptin/orphanin fq modulates the cardiovascular, but not renal, responses to stress in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 29:254–259PubMedGoogle Scholar
  56. Koizumi M, Midorikawa N, Takeshima H, Murphy NP (2004) Exogenous, but not endogenous nociceptin modulates mesolimbic dopamine release in mice. J Neurochem 89:257–263PubMedGoogle Scholar
  57. Koster A, Montkowski A, Schulz S, Stube EM, Knaudt K, Jenck F, Moreau JL, Nothacker HP, Civelli O, Reinscheid RK (1999) Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc Natl Acad Sci USA 96:10444–10449PubMedGoogle Scholar
  58. Le Maitre E, Vilpoux C, Costentin J, Leroux-Nicollet I (2005) Opioid receptor-like 1 (NOP) receptors in the rat dorsal raphe nucleus: evidence for localization on serotoninergic neurons and functional adaptation after 5,7-dihydroxytryptamine lesion. J Neurosci Res 9:9Google Scholar
  59. Levine J, Cole DP, Chengappa KN, Gershon S (2001) Anxiety disorders and major depression, together or apart. Depress Anxiety 14:94–104PubMedGoogle Scholar
  60. Mamiya T, Noda Y, Nishi M, Takeshima H, Nabeshima T (1998) Enhancement of spatial attention in nociceptin/orphanin FQ receptor-knockout mice. Brain Res 783:236–240PubMedGoogle Scholar
  61. Marti M, Stocchi S, Paganini F, Mela F, De Risi C, Calo’' G, Guerrini R, Barnes TA, Lambert DG, Beani L, Bianchi C, Morari M (2003) Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. Br J Pharmacol 138:91–98PubMedGoogle Scholar
  62. Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M, Mercuri NB, Rizzi A, Franchi G, Beani L, Bianchi C, Morari M (2004) Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci 24:6659–6666PubMedGoogle Scholar
  63. Martin-Fardon R, Ciccocioppo R, Massi M, Weiss F (2000) Nociceptin prevents stress-induced ethanol- but not cocaine-seeking behavior in rats. Neuroreport 11:1939–1943PubMedCrossRefGoogle Scholar
  64. Massi M, Panocka I, de Caro G (2000) The psychopharmacology of tachykinin NK-3 receptors in laboratory animals. Peptides 21:1597–1609PubMedGoogle Scholar
  65. McLeod RL, Parra LE, Mutter JC, Erickson CH, Carey GJ, Tulshian DB, Fawzi AB, Smith-Torhan A, Egan RW, Cuss FM, Hey JA (2001) Nociceptin inhibits cough in the guinea-pig by activation of ORL(1) receptors. Br J Pharmacol 132:1175–1178PubMedGoogle Scholar
  66. Mela F, Marti M, Ulazzi L, Vaccari E, Zucchini S, Trapella C, Salvadori S, Beani L, Bianchi C, Morari M (2004) Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex. Eur J Neurosci 19:1317–1324PubMedGoogle Scholar
  67. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monserrat B, Mazarguil H, Vassart G, Parmentier M, Costentin J (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377:532–535PubMedGoogle Scholar
  68. Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83–244PubMedGoogle Scholar
  69. Mogil JS, Nessim LA, Wilson SG (1999) Strain-dependent effects of supraspinal orphanin FQ/nociceptin on thermal nociceptive sensitivity in mice. Neurosci Lett 261:147–150PubMedGoogle Scholar
  70. Mollereau C, Mouledous L (2000) Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides 21:907–917PubMedGoogle Scholar
  71. Mombereau C, Kaupmann K, Froestl W, Sansig G, van der Putten H, Cryan JF (2004) Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 29:1050–1062PubMedGoogle Scholar
  72. Mombereau C, Kaupmann K, Gassmann M, Bettler B, van der Putten H, Cryan JF (2005) Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits. Neuroreport 16:307–310PubMedGoogle Scholar
  73. Moran TD, Abdulla FA, Smith PA (2000) Cellular neurophysiological actions of nociceptin/orphanin FQ. Peptides 21:969–976PubMedGoogle Scholar
  74. Muller MB, Wurst W (2004) Getting closer to affective disorders: the role of CRH receptor systems. Trends Mol Med 10:409–415PubMedGoogle Scholar
  75. Murphy NP, Lee Y, Maidment NT (1999) Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res 832:168–170PubMedGoogle Scholar
  76. Murphy NP, Lam HA, Chen Z, Pintar JE, Maidment NT (2002) Heroin-induced locomotion and mesolimbic dopamine release is unchanged in mice lacking the ORL.1 receptor gene. Brain Res 953:276–280PubMedGoogle Scholar
  77. Neal CR Jr, Mansour A, Reinscheid R, Nothacker HP, Civelli O, Akil H, Watson SJ Jr (1999a) Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol 412:563–605PubMedGoogle Scholar
  78. Neal CR Jr, Mansour A, Reinscheid R, Nothacker HP, Civelli O, Watson SJ Jr (1999b) Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurol 406:503–547PubMedGoogle Scholar
  79. New DC, Wong YH (2002) The ORL1 receptor: molecular pharmacology and signaling mechanisms. Neurosignals 11:197–212PubMedGoogle Scholar
  80. Nishi M, Houtani T, Noda Y, Mamiya T, Sato K, Doi T, Kuno J, Takeshima H, Nukada T, Nabeshima T, Yamashita T, Noda T, Sugimoto T (1997) Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor. EMBO J 16:1858–1864PubMedGoogle Scholar
  81. Nutt DJ (2002) The neuropharmacology of serotonin and noradrenyaline in depression. Int Clin Psychopharmacol 17:S1–12PubMedGoogle Scholar
  82. Nutt DJ (2005) Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 10:49–56PubMedGoogle Scholar
  83. Nutt DJ, Malizia AL (2001) New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179:390–396PubMedGoogle Scholar
  84. Okawa H, Kudo M, Kudo T, Guerrini R, Lambert DG, Kushikata T, Yoshida H, Matsuki A (2001) Effects of nociceptinNH2 and [Nphe1]nociceptin(1–13)NH2 on rat brain noradrenaline release in vivo and in vitro. Neurosci Lett 303:173–176PubMedGoogle Scholar
  85. Okuda-Ashitaka E, Minami T, Tachibana S, Yoshihara Y, Nishiuchi Y, Kimura T, Ito S (1998) Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature 392:286–289PubMedGoogle Scholar
  86. O’Neil MF, Moore NA (2003) Animal models of depression: are there any? Hum Psychopharmacol 18:239–254PubMedGoogle Scholar
  87. Osinski MA, Bass P, Gaumnitz EA (1999) Peripheral and central actions of orphanin FQ (nociceptin) on murine colon. Am J Physiol 276:G125–G131PubMedGoogle Scholar
  88. Ouagazzal AM, Moreau JL, Pauly-Evers M, Jenck F (2003) Impact of environmental housing conditions on the emotional responses of mice deficient for nociceptin/orphanin FQ peptide precursor gene. Behav Brain Res 144:111–117PubMedGoogle Scholar
  89. Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Azuma T, Ichikawa D, Nambu H, Iguchi T, Iwasawa Y, Ohta H (2000) In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur J Pharmacol 402:45–53PubMedGoogle Scholar
  90. Peluso J, LaForge KS, Matthes HW, Kreek MJ, Kieffer BL, Gaveriaux-Ruff C (1998) Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells. J Neuroimmunol 81:184–192PubMedGoogle Scholar
  91. Pomonis JD, Billington CJ, Levine AS (1996) Orphanin FQ, agonist of orphan opioid receptor ORL1, stimulates feeding in rats. Neuroreport 8:369–371PubMedGoogle Scholar
  92. Redrobe JP, Calo’ G, Regoli D, Quirion R (2002) Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn-Schmiedeberg’s Arch Pharmacol 365:164–167Google Scholar
  93. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O (1995) Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270:792–794PubMedGoogle Scholar
  94. Renard CE, Dailly E, David DJ, Hascoet M, Bourin M (2003) Monoamine metabolism changes following the mouse forced swimming test but not the tail suspension test. Fundam Clin Pharmacol 17:449–455PubMedGoogle Scholar
  95. Ressler KJ, Nemeroff CB (2000) Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 1:2–19Google Scholar
  96. Rex A, Marsden CA, Fink H (1993) Effect of diazepam on cortical 5-HT release and behaviour in the guinea-pig on exposure to the elevated plus maze. Psychopharmacology (Berl) 110:490–496Google Scholar
  97. Rizzi A, Bigoni R, Marzola G, Guerrini R, Salvadori S, Regoli D, Calo’ G (2001a) Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice. Naunyn-Schmiedeberg’s Arch Pharmacol 363:161–165Google Scholar
  98. Rizzi A, Marzola G, Bigoni R, Guerrini R, Salvadori S, Mogil JS, Regoli D, Calo’ G (2001b) Endogenous nociceptin signaling and stress-induced analgesia. Neuroreport 12:3009–3013PubMedGoogle Scholar
  99. Rodgers RJ (1997) Animal models of ‘anxiety’: where next? Behav Pharmacol 8:477–496; discussion 497–504PubMedGoogle Scholar
  100. Rominger A, Forster S, Zentner J, Dooley DJ, McKnight AT, Feuerstein TJ, Jackisch R, Vlaskovska M (2002) Comparison of the ORL1 receptor-mediated inhibition of noradrenaline release in human and rat neocortical slices. Br J Pharmacol 135:800–806PubMedGoogle Scholar
  101. Rupniak NM (2002) New insights into the antidepressant actions of substance P (NK1 receptor) antagonists. Can J Physiol Pharmacol 80:489–494PubMedGoogle Scholar
  102. Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, Kamei J (2004) Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J Pharmacol Sci 95:374–380PubMedGoogle Scholar
  103. Sandin J, Georgieva J, Schott PA, Ogren SO, Terenius L (1997) Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats. Eur J Neurosci 9:194–197PubMedGoogle Scholar
  104. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805–809PubMedGoogle Scholar
  105. Sbrenna S, Marti M, Morari M, Calo’ G, Guerrini R, Beani L, Bianchi C (2000) Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin. Br J Pharmacol 130:425–433PubMedGoogle Scholar
  106. Schlicker E, Morari M (2000) Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system. Peptides 21:1023–1029PubMedGoogle Scholar
  107. Schlicker E, Classen K, Gothert M (1984) GABAB receptor-mediated inhibition of serotonin release in the rat brain. Naunyn-Schmiedeberg’s Arch Pharmacol 326:99–105Google Scholar
  108. Schlicker E, Werthwein S, Kathmann M, Bauer U (1998) Nociceptin inhibits noradrenaline release in the mouse brain cortex via presynaptic ORL1 receptors. Naunyn-Schmiedeberg’s Arch Pharmacol 358:418–422Google Scholar
  109. Serrats J, Artigas F, Mengod G, Cortes R (2003) GABAB receptor mRNA in the raphe nuclei: co-expression with serotonin transporter and glutamic acid decarboxylase. J Neurochem 84:743–752PubMedGoogle Scholar
  110. Siniscalchi A, Rodi D, Beani L, Bianchi C (1999) Inhibitory effect of nociceptin on [3H]-5-HT release from rat cerebral cortex slices. Br J Pharmacol 128:119–123PubMedGoogle Scholar
  111. Siniscalchi A, Rodi D, Morari M, Marti M, Cavallini S, Marino S, Beani L, Bianchi C (2002) Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro. Br J Pharmacol 136:1178–1184PubMedGoogle Scholar
  112. Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F, Poncelet M, Gueudet C, Desvignes C, Le Fur G, Soubrie P (2001) Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 299:449–458PubMedGoogle Scholar
  113. Valentino RJ, Commons KG (2005) Peptides that fine-tune the serotonin system. Neuropeptides 39:1–8PubMedGoogle Scholar
  114. Varty GB, Hyde LA, Hodgson RA, Lu SX, McCool MF, Kazdoba TM, Del Vecchio RA, Guthrie DH, Pond AJ, Grzelak ME, Xu X, Korfmacher WA, Tulshian D, Parker EM, Higgins GA (2005) Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psychopharmacology 15:1–12Google Scholar
  115. Vaughan CW, Christie MJ (1996) Increase by the ORL1 receptor (opioid receptor-like1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones. Br J Pharmacol 117:1609–1611PubMedGoogle Scholar
  116. Vitale G, Filaferro M, Frigieri G, Arletti R (2003) Is nociceptin/orphanin FQ, at low doses, anxiogenic rather than anxiolytic? VIII Convegno Monotematico della Societa Italiana di Farmacologia. Camerino, Italy (15 Sept), p 11Google Scholar
  117. Werthwein S, Bauer U, Nakazi M, Kathmann M, Schlicker E (1999) Further characterization of the ORL1 receptor-mediated inhibition of noradrenaline release in the mouse brain in vitro. Br J Pharmacol 127:300–308PubMedGoogle Scholar
  118. Wichmann J, Adam G, Rover S, Hennig M, SCalo’ne M, Cesura AM, Dautzenberg FM, Jenck F (2000) Synthesis of (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties. Eur J Med Chem 35:839–851PubMedGoogle Scholar
  119. Williams JT, Colmers WF, Pan ZZ (1988) Voltage- and ligand-activated inwardly rectifying currents in dorsal raphe neurons in vitro. J Neurosci 8:3499–3506PubMedGoogle Scholar
  120. Witta J, Palkovits M, Rosenberger J, Cox BM (2004) Distribution of nociceptin/orphanin FQ in adult human brain. Brain Res 997:24–29PubMedGoogle Scholar
  121. Wright IK, Upton N, Marsden CA (1992) Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in the ventral hippocampus of rats during behaviour on the elevated X-maze. Psychopharmacology (Berl) 109:338–346Google Scholar
  122. Zaveri N (2003) Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci 73:663–678PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Department of Experimental and Clinical Medicine, Section of Pharmacology and Neuroscience CenterUniversity of FerraraFerraraItaly

Personalised recommendations